Welcome to our dedicated page for Ptc Therapeutics news (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on Ptc Therapeutics stock.
PTC Therapeutics develops and commercializes medicines for children and adults with rare disorders, with a life-science business focused on clinically differentiated therapies in areas including neurology and metabolism. Company news commonly covers product revenue, commercial launch activity, financial guidance, investor presentations, and updates from its rare-disease development portfolio.
Recurring developments include Sephience™ (sepiapterin) launch and revenue updates, clinical and regulatory disclosures involving votoplam, vatiquinone and Translarna™ (ataluren), and partnership-related program responsibilities. PTC also reports governance changes and Nasdaq inducement equity grants tied to employee compensation.
PTC Therapeutics (NASDAQ: PTCT) announced the publication of results from Part 2 of the FIREFISH study in the New England Journal of Medicine. The trial demonstrated that infants with symptomatic Type 1 spinal muscular atrophy (SMA) treated with Evrysdi™ showed notable enhancements in survival and motor function compared to historical controls. Key findings include a 90% increase in CHOP-INTEND scores and 85% event-free survival after 12 months. PTC's splicing platform plays a crucial role in developing innovative therapies for SMA.
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call on July 29, 2021, at 4:30 p.m. (ET) to report its second quarter 2021 financial results and update on business outlook. Interested participants can access the call by dialing (877) 303-9216 domestically or (973) 935-8152 internationally. The call will also be available via a live webcast on the company's website, with a replay accessible two hours post-call. The event underscores PTC's dedication to providing updates on its pipeline and business strategy focused on rare disorders.
PTC Therapeutics (NASDAQ: PTCT) released new data confirming the clinical benefits of EMFLAZA® (deflazacort) for Duchenne muscular dystrophy (DMD) patients over prednisone. The pooled results showed significant improvement in physical performance metrics, including the six-minute walk test and the North Star Ambulatory Assessment. Experts emphasized the advantages of early EMFLAZA initiation for better patient outcomes. The data also highlighted real-world evidence of EMFLAZA's effectiveness and its role in slowing disease progression in DMD patients.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced the approval of Evrysdi™ (risdiplam) in Japan for treating spinal muscular atrophy (SMA). This approval, based on pivotal studies in infants and adults, will trigger a $10M milestone payment from Roche. Evrysdi provides an at-home oral treatment option, enhancing accessibility for patients. It has previously gained FDA and EMA approvals for patients aged 2 months and older. SMA, a severe neuromuscular disease, affects approximately 1 in 10,000 babies, making this development significant for patient care.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced on June 11, 2021, the approval of non-statutory stock options for 118,350 shares and 30,835 restricted stock units (RSUs) to 66 new employees. These grants are part of the employment compensation to attract talent under NASDAQ's inducement grant exception. The stock options have an exercise price of $42.95 and vest over four years, while RSUs vest annually. This initiative aims to enhance PTC's workforce as it focuses on developing innovative treatments for rare disorders, supporting its growth strategy and commitment to patient care.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced positive interim results from the RAINBOWFISH trial, showing that pre-symptomatic infants with spinal muscular atrophy (SMA) achieved significant motor milestones after treatment with Evrysdi. These milestones include sitting, rolling, crawling, standing, and walking independently. Additionally, interim results from the JEWELFISH safety study show stabilization in motor function and increased SMN protein levels. Evrysdi is FDA-approved for SMA patients aged 2 months and older and is marketed by Genentech.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced the election of Mary L. Smith to its Board of Directors on June 9, 2021. Smith brings extensive experience from her role as Principal Deputy Director at the Indian Health Service, where she oversaw a $6 billion healthcare division. Currently, she serves as Vice Chair at VENG Group, advising on business strategy and healthcare governance. Smith aims to leverage her background to support PTC's mission in advancing its pipeline of medicines for rare diseases. CEO Stuart W. Peltz emphasized her valuable insights for the company's growth.
PTC Therapeutics announced that the FDA and European Commission have granted Orphan Drug Designation (ODD) for PTC923, aimed at treating hyperphenylalaninemia, primarily caused by Phenylketonuria (PKU). PKU can lead to severe cognitive disabilities and seizures. PTC923, an oral synthetic sepiapterin, is expected to enter a Phase 3 trial, APHENITY, in mid-2021. ODD provides various benefits, including grant funding, tax advantages, and potential market exclusivity in both the U.S. and EU.
PTC Therapeutics, based in South Plainfield, N.J., will present a company overview at the William Blair 41st Annual Growth Stock Conference on June 2, 2021, at 3:40 p.m. ET. The presentation will be accessible via a live webcast on their website and available for archiving for 30 days post-event. PTC is dedicated to developing innovative treatments for rare disorders and emphasizes maximizing patient access to its medicines.
PTC Therapeutics, Inc. (NASDAQ: PTCT) revealed findings on the impact of caring for children with aromatic L-Amino acid decarboxylase deficiency (AADC-d) at the Virtual ISPOR North America 2021 Conference. The study highlights that caregivers dedicate an average of 105 hours weekly to support, often leading 75% to leave jobs or reduce hours. The findings underscore the critical need for effective treatments, as AADC-d causes severe disabilities and requires constant care. Data also show a positive correlation between treatment efficacy and improved health outcomes for affected children.